The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele

Cell Death and Differentiation

Volumn 21, Issue 9, 2014, Pages 1419-1431

  Shetzer, Y ^a   Kagan, S ^a   Koifman, G ^a   Sarig, R ^a   Kogan Sakin, I ^a   Charni, M ^a   Kaufman, T ^a   Zapatka, M ^b   Molchadsky, A ^a   Rivlin, N ^a   Dinowitz, N ^a   Levin, S ^a   Landan, G ^a   Goldstein, I ^a   Goldfinger, N ^a   Pe'Er, D ^c   Radlwimmer, B ^b   Lichter, P ^b   Rotter, V ^a   Aloni Grinstein, R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Department of Biological Sciences Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELE; ANIMAL; C57BL MOUSE; GENETICS; HETEROZYGOSITY LOSS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; NUDE MOUSE; SCID MOUSE; STEM CELL;

ALLELES; ANIMALS; LOSS OF HETEROZYGOSITY; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905900572     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.57     Document Type: Article

References (56)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011; 476: 163-169.
3. Berger AH, Pandolfi PP. Haplo-insufficiency: a driving force in cancer. J Pathol 2011; 223: 137-146.
4. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med 2009; 15: 120-128.
5. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
6. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
7. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
8. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer 1997; 76: 1-14.
9. Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc Natl Acad Sci USA 2002; 99: 3586-3590.
10. Giachino C, Orlando L, Turinetto V. Maintenance of genomic stability in mouse embryonic stem cells: relevance in aging and disease. Int J Mol Sci 2013; 14: 2617-2636.
11. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
12. Som A, Wen S, Tu SM. Stem cell origin of testicular seminoma. Clin Genitourin Cancer 2013; 11: 489-494.
13. Stange DE, Clevers H. The Yin and Yang of intestinal (cancer) stem cells and their progenitors. Stem Cells 2013; 31: 2287-2295.
14. Rodriguez R, Rubio R, Masip M, Catalina P, Nieto A, de la Cueva T et al. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia 2009; 11: 397-407.
15. Rodriguez R, Rubio R, Menendez P. Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res 2012; 22: 62-77.
16. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, Catalina P et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 2010; 70: 4185-4194.
17. Rubio R, Gutierrez-Aranda I, Saez-Castillo AI, Labarga A, Rosu-Myles M, Gonzalez-Garcia S et al. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene 2012; 32: 4970-4980.
18. Li H, Fan X, Kovi RC, Jo Y, Moquin B, Konz R et al. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: A model of age-related tumorigenesis in mice. Cancer Res 2007; 67: 10889-10898.
19. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
20. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448: 318-324.
21. Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7: 521-531.
22. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8: 106-118.
23. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
24. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-67.
25. Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 2010; 207: 2127-2140.
26. Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature 2009; 460: 1085-1086.
27. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009; 462: 595-601.
28. Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S et al. p53 Counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ 2012; 20: 312-320.
29. Liyanage M, Coleman A, du Manoir S, Veldman T, McCormack S, Dickson RB et al. Multicolour spectral karyotyping of mouse chromosomes. Nat Genet 1996; 14: 312-315.
30. Rotter V, Wolf D, Pravtcheva D, Ruddle FH. Chromosomal assignment of the murine gene encoding the transformation-related protein p53. Mol Cell Biol 1984; 4: 383-385.
31. Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni Syndrome. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K (eds) GeneReviews. Seattle (WA), University of Washington, 1993.
32. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006; 6: 99-106.
33. Brosh R, Rotter V. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Mol bioSystems 2010; 6: 17-29.
34. Yang YG, Herceg Z, Nakanishi K, Demuth I, Piccoli C, Michelon J et al. The Fanconi anemia group A protein modulates homologous repair of DNA double-strand breaks in mammalian cells. Carcinogenesis 2005; 26: 1731-1740.
35. Tischfield JA. Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. Am J Hum Genet 1997; 61: 995-999.
36. Okabe I, Bailey LC, Attree O, Srinivasan S, Perkel JM, Laurent BC et al. Cloning of human and bovine homologs of SNF2/SWI2: a global activator of transcription in yeast S. cerevisiae. Nucleic Acids Res 1992; 20: 4649-4655.
37. van Boxtel R, Kuiper RV, Toonen PW, van Heesch S, Hermsen R, de Bruin A et al. Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency. Am J Pathol 2011; 179: 1616-1622.
38. Armesilla-Diaz A, Elvira G, Silva A. p53 regulates the proliferation, differentiation and spontaneous transformation of mesenchymal stem cells. Exp Cell Res 2009; 315: 3598-3610.
39. Wilson A, Shehadeh LA, Yu H, Webster KA. Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells. BMC Genomics 2010; 11: 229.
40. McMurray MA, Gottschling DE. An age-induced switch to a hyper-recombinational state. Science 2003; 301: 1908-1911.
41. Yan H, Jin H, Xue G, Mei Q, Ding F, Hao L et al. Germline hMSH2 promoter mutation in a Chinese HNPCC kindred: evidence for dual role of LOH. Clin Genet 2007; 72: 556-561.
42. Sanchez de Abajo A, de la Hoya M, van Puijenbroek M, Godino J, Diaz-Rubio E, Morreau H et al. Dual role of LOH at MMR loci in hereditary non-polyposis colorectal cancer? Oncogene 2006; 25: 2124-2130.
43. Boettger MB, Sergi C, Meyer P. BRCA1/2 mutation screening and LOH analysis of lung adenocarcinoma tissue in a multiple-cancer patient with a strong family history of breast cancer. J Carcinog 2003; 2: 5.
44. Clarke CL, Sandle J, Jones AA, Sofronis A, Patani NR, Lakhani SR. Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers. Br J Cancer 2006; 95: 515-519.
45. Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012; 44: 475-476; author reply 476.
46. Preston CR, Flores C, Engels WR. Age-dependent usage of double-strand-break repair pathways. Curr Biol 2006; 16: 2009-2015.
47. Gonzalez F, Georgieva D, Vanoli F, Shi ZD, Stadtfeld M, Ludwig T et al. Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Rep 2013; 3: 651-660.
48. Erdel F, Rippe K. Binding kinetics of human ISWI chromatin-remodelers to DNA repair sites elucidate their target location mechanism. Nucleus 2011; 2: 105-112.
49. Toiber D, Erdel F, Bouazoune K, Silberman DM, Zhong L, Mulligan P et al. SIRT6 Recruits SNF2H to DNA Break Sites, Preventing Genomic Instability through Chromatin Remodeling. Mol Cell 2013; 51: 454-468.
50. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009; 27: 543-549.
51. Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci USA 2006; 103: 16406-16411.
52. Kochupurakkal BS, Sarig R, Fuchs O, Piestun D, Rechavi G, Givol D. Nanog inhibits the switch of myogenic cells towards the osteogenic lineage. Biochem Biophys Res Commun 2008; 365: 846-850.
53. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
54. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148: 59-71.
55. Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45: 927-932.
56. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003; 31: 265-273.